Femasys (NASDAQ:FEMY) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Femasys (NASDAQ:FEMY) released its earnings results on Thursday. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.02, Zacks reports. The firm had revenue of $0.58 million during the quarter, compared to analyst estimates of $1.66 million. Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%.

Femasys Stock Performance

FEMY stock opened at $1.29 on Friday. The firm has a market cap of $29.54 million, a price-to-earnings ratio of -1.59 and a beta of -2.85. Femasys has a twelve month low of $0.86 and a twelve month high of $1.84. The company has a quick ratio of 3.26, a current ratio of 3.94 and a debt-to-equity ratio of 0.86. The business’s fifty day simple moving average is $1.41 and its two-hundred day simple moving average is $1.22.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Femasys in a research note on Friday.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.